SNNLive caught up with Geert Kersten, CEO of CEL-SCI Corporation (NYSE American: CVM) via Zoom, to discuss recent news including: Phase 3 Head and Neck Cancer Study, developing immunotherapy for COVID-19 Coronavirus infection, 2nd quarter fiscal 2020 financial results and company performance, and what investors should look for moving forward.
For more information about CEL-SCI Corporation, please visit:
The interview may contain forward looking statements about CEL-SCI Corporation. See CEL-SCI’s periodic filings with the Securities and Exchange Commission for more complete information.
About CEL-SCI Corporation
CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine first, BEFORE they received surgery, radiation and/or chemotherapy. This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection), has received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck.
CEL-SCI believes that this Phase 3 study is the largest Phase 3 study in the world for the treatment of head and neck cancer. Per the study’s protocol, newly diagnosed patients with advanced primary squamous cell carcinoma of the head and neck were treated with the Multikine treatment regimen for 3 weeks prior to receiving the Standard of Care (SOC) which involves surgery, radiation or concurrent radiochemotherapy. Multikine is designed to help the immune system “see” the tumor at a time when the immune system is still relatively intact and thereby thought to better be able to mount an attack on the tumor. The aim of treatment with Multikine is to boost the body’s immune system prior to SOC. The Phase 3 study is fully enrolled with 928 patients and the last patient was treated in September 2016. To prove an overall survival benefit, the study requires CEL-SCI to wait until 298 events have occurred among the two main comparator groups.
The Company’s LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment of COVID-19 in hospitalized and at-high-risk patients. The Company has operations in Vienna, Virginia, and near/in Baltimore, Maryland.
Subscribe NOW to SNN Network:
New videos are added almost every day to the SNN Network channel sharing fascinating stories and companies from the MicroCap stock market.
Get more SNN Network:
Website:
Follow Stock News Now:
Like Stock News Now:
Follow Stock News Now on LinkedIn:
Follow Stock News Now on StockTwits:
SNN.Network is the Official YouTube Channel for the Small-, Micro- and Nano-cap markets by providing news, insights, education tools and expert commentary. Subscribe now to be notified when new CEO video interviews, WALL STREET VIEWS with investing experts and new episodes of the Planet MicroCap Podcast are LIVE!
